Santen, an Emeryville, Calif.-based subsidiary of Japan-based Santen Pharmaceuticals, has entered into a research collaboration agreement with Clearside Biomedical of Alpharetta, Georgia, a company in which Santen, along with other financial backers, is also making an investment. Specifically, Clearside’s “microinjection platform,” which provides access to the retina and choroid, just attracted $7.9 million in fresh funding from Santen, Mountain Group Capital, Hatteras Venture Partners, Georgia Research Alliance Fund, and Kenan Flagler Business School Private Equity Fund.

NXT Capital’s venture finance group has provided financing to support Clinipace Worldwide’s acquisition of Paragon Biomedical. Digital contract research organization Clinipace is headquartered in Morrisville, North Carolina and is backed by Morgan Stanley Expansion Capital, Hatteras Venture Partners, Brooke Private Equity, Osage Venture Partners and Mario Family Partners.

Clinverse said Monday that it has closed $3.8 million in Series B round of funding led by Hatteras Venture Partners. Vital Financial also participated in the round. Raleigh, N.C.-based Clinverse provides cloud-based financial management and payment services for the clinical trials industry. PRESS RELEASE Clinverse, Inc., the global cloud-based ecommerce platform provider for clinical trials, [...]

SugarSync, whose free service allows you to sync your data across computers, mobile phones and other devices, has raised $15 million in Series D financing. New investor Coral Group led the round, with existing investors Draper Fisher Jurvetson, Sigma Partners, Hatteras Venture Partners and Hercules participating. The company has raised a total of $50 million [...]

Clinipace Worldwide, a digital clinical research organization, has raised $15 million in Series C financing. Morgan Stanley Expansion Capital led the round, which included participation from Durham, N.C.-based Hatteras Venture Partners, and Boston-based Brook Private Equity Advisors. The company will use the money to expand its contract research services. The company is based in Research Triangle Park, N.C.

The VC fundraising environment is looking weak, with just a smattering of announcements and regulatory filings over the past two months. Official Q3 stats won’t be released until October, but it’s not looking good from an anecdotal standpoint. Trolling through the peHUB archive, I turned up just five stories about various U.S.-based VC funds getting [...]

Hatteras Venture Partners announced the first close of its fourth fund with $74 million in subscriptions. The final target for HVP IV is $125 million. Hatteras, of Durham, N.C., invests in seed stage companies and projects in the field of human medicine and life sciences.

PhaseBio Pharmaceuticals has closed a $25 million Series B round after adding $15 million in venture capital and nearly $500,000 in grants. The company, based in Malvern, Penn., is developing drugs to treat diabetes, metabolic disease and cardiovascular disease. Investors include Astellas Venture Management, Johnson & Johnson Development Corporation, Hatteras Venture Partners and Fletcher Spaght Ventures.